Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14639737 | 1.00 | TDP1 (0.38) | TDP1PABPC1APOBEC3AAPOBEC3GTSHR | |
| SCHEMBL7332966 | 1.00 | TDP1 (0.38) | TDP1PABPC1APOBEC3AAPOBEC3GTSHR | |
| SCHEMBL7332971 | 1.00 | TDP1 (0.38) | TDP1PABPC1APOBEC3AAPOBEC3GTSHR | |
| SCHEMBL30158913 | 0.85 | — | — | |
| SCHEMBL17425140 | 0.79 | MEN1 (0.30) | — | |
| SCHEMBL2520828 | 0.77 | — | — | |
| SCHEMBL9501178 | 0.76 | CHRNB2 (0.40) | — | |
| SCHEMBL7295327 | 0.76 | TSHR (0.30) | TSHR | |
| SCHEMBL14639634 | 0.76 | TDP1 (0.38) | TDP1PABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL7295356 | 0.76 | TSHR (0.30) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6090828-A | ARTHERIOSCLEROSIS | REITZ DAVID B (US) | 2000-07-18 | — | — | US | disclosed |
| US-5583248-A | Amino acid derivatives having antiviral activity | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5451593-A | Method of using 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of a glaucoma disorder | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5451591-A | Method of using 5-arylheteroarylalkyl-1,3 5-trisubstituted-1,24-triazole compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0512343-B1 | Amino acid derivatives and their use as anti-viral agents | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | EP | disclosed |
| US-5430041-A | Amino acid derivatives having antiviral activity | HOFFMANN-LA ROCHE INC. (US) | 1995-07-04 | — | — | US | disclosed |
| US-5196537-A | Angiotensin/II/ antagonists; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-03-23 | — | — | US | disclosed |
| WO-1992016523-A1 | 5-ARYLHETEROARYLALKYL-1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |